Ronald P. DeMatteo

University of Pennsylvania — United States

Medicine · Health Sciences

138h-index75.3kcitations939works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastrointestinal Tumor Research and Treatment(285), Hepatocellular Carcinoma Treatment and Prognosis(210), Cholangiocarcinoma and Gallbladder Cancer Studies(182), Pancreatic and Hepatic Oncology Research(173), Sarcoma Diagnosis and Treatment(97)

Publications937 total

Dual pancreatic carcinomas: clonally related or independent primaries?
npj Precision Oncology·2026Open Access
Agonistic CD40 elicits CD8+ T-cell-dependent primary responses and CD4+ T-cell-dependent long-term immunity in breast cancer
npj Breast Cancer·2026Open Access
Supplemental Figure 3 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplemental Figure 5 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplemental Figure 1 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplemental Figure 7 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplemental Figure 6 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplemental Figure 8 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplemental Figure 2 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplemental Figure 4 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout
Cancers·2025· 1 citedOpen Access
Predictors of malignancy in patients undergoing surgery for Mirizzi syndrome
Journal of Gastrointestinal Surgery·2025
CD40 agonism enhances immune checkpoint blockade and generates immunologic memory via CD4+ T cells in ERα+ mammary tumors
2025Open Access
Histologic- and Genomic-Directed Adjuvant Therapy for Ampullary Adenocarcinoma: A Hidden Genome–Derived Analysis
Journal of the National Comprehensive Cancer Network·2025· 1 citedOpen Access
Conduct of Open Hepatic Arterial Infusion Pump Placement
2025
Surgical Management of Sarcoma Metastatic to Liver
Hematology/Oncology Clinics of North America·2024
Supplemental Figure 7 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in <i>PDGFRA D842V</i>-mutant gastrointestinal stromal tumor
2024Open Access
Supplemental Figure 1 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in <i>PDGFRA D842V</i>-mutant gastrointestinal stromal tumor
2024Open Access
Supplemental Figure 6 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in <i>PDGFRA D842V</i>-mutant gastrointestinal stromal tumor
2024Open Access
Supplemental Figure 8 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in <i>PDGFRA D842V</i>-mutant gastrointestinal stromal tumor
2024Open Access
page 1 of 47Next →

Frequent Co-authors

William R. Jarnagin(24), Yuman Fong(21), Mithat Gönen(20), Leslie H. Blumgart(18), Murray F. Brennan(12), Cristina R. Antonescu(11), Robert G. Maki(11), Peter J. Allen(8), Michael I. D’Angelica(7), Michael I. D’Angelica(6), Peter Besmer(6), George D. Demetri(5), David S. Klimstra(5), Samuel Singer(5), Jedd D. Wolchok(4), Vinod P. Balachandran(4), Peter W. T. Pisters(4), Margaret von Mehren(4), Nuh N. Rahbari(3), O. James Garden(3)